ADVM Adverum Biotechnologies Inc.

3.50
+0.05  (1%)
Previous Close 3.45
Open 3.40
Price To book 0.79
Market Cap 151503751
Shares 43,286,786
Volume 112,947
Short Ratio 3.20
Av. Daily Volume 224,946

SEC filingsSee all SEC filings

  1. 8-K - Current report 171074421
  2. 8-K - Current report 171066988
  3. 424B5 - Prospectus [Rule 424(b)(5)] 171047663
  4. EFFECT - Notice of Effectiveness 171046133
  5. S-3/A [Amend] - Registration statement under Securities Act of 1933 171039281

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial to be initiated 4Q 2017.
ADVM-043
Alpha-1 Antitrypsin (A1AT) Deficiency
Phase 2a negative data released June 2015 (met primary endpoint but increase in retinal thickness). As a result Phase 2b development will not proceed.
AVA-101
Wet age-related macular degeneration (Wet-AMD)

SEC Filings

  1. 8-K - Current report 171074421
  2. 8-K - Current report 171066988
  3. 424B5 - Prospectus [Rule 424(b)(5)] 171047663
  4. EFFECT - Notice of Effectiveness 171046133
  5. S-3/A [Amend] - Registration statement under Securities Act of 1933 171039281
  6. S-3 - Registration statement under Securities Act of 1933 171022326
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 171015555
  8. 8-K - Current report 171014753
  9. CT ORDER - Confidential treatment order 17975406
  10. 8-K - Current report 17919920